Can Repatha (evolocumab) be used with Bildyos (denosumab)?
Yes, Repatha (evolocumab) can be safely used concurrently with Bildyos (denosumab) as there are no known drug-drug interactions between these two medications and they work through completely different mechanisms for different indications.
Mechanism and Safety Profile
Evolocumab is a PCSK9 inhibitor that works by increasing LDL receptor availability to lower cholesterol 1, while denosumab is a RANK ligand inhibitor that prevents bone resorption to treat osteoporosis 2. These medications target entirely separate physiological pathways with no overlapping mechanisms of action.
Evidence Supporting Concurrent Use
The FDA label for Bildyos does not list evolocumab or any PCSK9 inhibitors as contraindicated medications or drug-drug interactions 2. Similarly, the 2022 ACC guidelines on PCSK9 inhibitors document drug interactions with cyclosporine, fibrates, and bile acid sequestrants for other lipid-lowering agents, but make no mention of interactions with bone-targeted therapies like denosumab 1.
Research specifically examining concurrent biologic therapy with denosumab in patients with rheumatoid arthritis found no increased infection risk when denosumab was used alongside other biologic agents 3, suggesting that combining biologics targeting different pathways is generally safe when clinically indicated.
Clinical Considerations
Key Monitoring Points:
For Bildyos: Monitor serum calcium levels closely, especially in patients with chronic kidney disease (eGFR < 30 mL/min), as severe hypocalcemia is a major risk. Ensure adequate calcium (1000 mg daily) and vitamin D (at least 400 IU daily) supplementation 2
For Repatha: Monitor LDL-C levels to assess therapeutic response. The medication is generally well-tolerated with common adverse effects including nasopharyngitis, injection site reactions, and upper respiratory infections 1
Important Caveats:
- Both medications are administered subcutaneously but on different schedules (Bildyos every 6 months, Repatha every 2 weeks or monthly)
- Patients should not receive other denosumab products concurrently with Bildyos 2
- If Bildyos is discontinued, transition to another antiresorptive agent to prevent multiple vertebral fractures from rebound bone loss 2
The combination is appropriate when a patient has both high cardiovascular risk requiring intensive LDL-C lowering and high fracture risk requiring osteoporosis treatment. There is no need to avoid concurrent use or adjust dosing of either medication.